EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Single domain antibody: Development and application in biotechnology and biopharma

Ting Yu, Fang Zheng, Wenbo He, Serge Muyldermans, Yurong Wen iD

Immunological Reviews · 2024-11 · 328 (1) · 98-112

DOI: 10.1111/imr.13381 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 21.08.2024. Verfasst von Ting Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Microbiome Research of Med-X Institute, Shaanxi Provincial Key Laboratory of Sepsis in Critical Care Medicine, The First Affiliated Hospit…. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Biotechnology. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shaanxi Province Natural Science, Institutional Foundation of the First Affiliated Hospital of Xi'an Jiaotong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heavy‐chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains‐only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb). These functional HCAbs, serendipitous discovered about three decades ago, are exclusively found in camelids, comprising dromedaries, camels, llamas, and vicugnas. Nanobodies have become an essential tool in biomedical research and medicine, both in diagnostics and therapeutics due to their beneficial properties: small size, high stability, strong antigen‐binding affinity, low immunogenicity, low production cost, and straightforward engineering into more potent affinity reagents. The occurrence of HCAbs in camelids remains intriguing. It is believed to be an evolutionary adaptation, equipping camelids with a robust adaptive immune defense suitable to respond to the pressure from a pathogenic invasion necessitating a more profound antigen recognition and neutralization. This evolutionary innovation led to a simplified HCAb structure, possibly supported by genetic mutations and drift, allowing adaptive mutation and diversification in the heavy chain variable gene and constant gene regions. Beyond understanding their origins, the application of nanobodies has significantly advanced over the past 30 years. Alongside expanding laboratory research, there has been a rapid increase in patent application for nanobodies. The introduction of commercial nanobody drugs such as Cablivi, Nanozora, Envafolimab, and Carvykti has boosted confidence among in their potential. This review explores the evolutionary history of HCAbs, their ontogeny, and applications in biotechnology and pharmaceuticals, focusing on approved and ongoing medical research pipelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesBiotechnologyAnimalsHumansProtein EngineeringImmunoglobulin Heavy Chains

Stichwörter der Autor:innen

VHHbiotechnological toolsdiagnosisheavy chain antibodiesnanobodysingle‐domain antibodytherapeutics

Substanzen

Single-Domain AntibodiesImmunoglobulin Heavy Chains

Autor:innen und Institutionen

  • Center for Microbiome Research of Med-X Institute, Shaanxi Provincial Key Laboratory of Sepsis in Critical Care Medicine, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
  • The Key Laboratory of Environment and Genes Related to Disease of Ministry of Education, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
  • Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.

ORCID-Profile: Yurong Wen

Förderung

  • National Natural Science Foundation of China
  • Shaanxi Province Natural Science
  • Institutional Foundation of the First Affiliated Hospital of Xi'an Jiaotong University

Zitieren

APA

Yu, T., Zheng, F., He, W., Muyldermans, S., & Wen, Y. (2024). Single domain antibody: Development and application in biotechnology and biopharma. Immunological Reviews, 328(1), 98-112. https://doi.org/10.1111/imr.13381

Vancouver

Yu T, Zheng F, He W, Muyldermans S, Wen Y. Single domain antibody: Development and application in biotechnology and biopharma. Immunological Reviews. 2024;328(1):98-112. doi:10.1111/imr.13381

BibTeX
@article{Yu2024,
  author = {Yu, Ting and Zheng, Fang and He, Wenbo and Muyldermans, Serge and Wen, Yurong},
  title = {Single domain antibody: Development and application in biotechnology and biopharma},
  journal = {Immunological Reviews},
  year = {2024},
  volume = {328},
  number = {1},
  pages = {98--112},
  doi = {10.1111/imr.13381}
}
Kostenlos starten →